The premise seemed elegant: require pharmaceutical manufacturers to disclose the data behind drug price increases, and the resulting transparency would discipline pricing behavior. By the mid-2020s, more than thirty states had enacted some form of drug pricing transparency legislation. The disclosures are arriving. The discipline has not.
The reason is not that the laws are poorly designed, though some are. The reason is that transparency in drug pricing is a necessary but insufficient condition for accountability, and the distance between disclosure and understanding is larger than most legislators anticipated. State drug price transparency programs have generated a substantial volume of data about pricing decisions — but data is not the same as information, and information is not the same as insight.
The typical state transparency law requires manufacturers to report when a drug’s WAC increases above a specified threshold — often ten to twenty percent annually — and to provide a justification for the increase. Some laws extend reporting requirements to new drug launches above a price threshold. Some require disclosure of R&D costs, marketing expenditures, and other financial inputs that the manufacturer claims justify the price. A few require PBMs to report rebate information, adding another layer of disclosure to the supply chain.
The resulting filings, when they are publicly accessible, reveal exactly what the informed observer would predict: manufacturers cite a combination of R&D investment, manufacturing complexity, market dynamics, and the value the drug delivers to patients. The justifications are formulaic because the law requires a justification without specifying what would constitute a satisfactory one. A manufacturer that reports a fifteen percent WAC increase and attributes it to “continued investment in the therapeutic area” has complied with the letter of the statute while disclosing nothing that the market did not already know.
The more substantive filings — those that include cost breakdowns, revenue data, or net price information — face a different problem. Drug pricing economics operate across multiple segments simultaneously. A manufacturer’s pricing decision for a given drug reflects the interaction between WAC, commercial rebates, Medicaid rebate obligations, 340B ceiling prices, Part B reimbursement dynamics, formulary tier positioning, and competitive pressure from therapeutic alternatives. Disclosing WAC and the size of its increase, without the full gross-to-net context, provides a partial picture that can be misleading in either direction. A large WAC increase may accompany a flat or declining net price if rebates increase proportionally. A modest WAC increase may be more consequential if it occurs on a drug with narrow rebate exposure.
The states that have attempted to require net price or rebate disclosure have encountered fierce resistance from manufacturers and PBMs, both of whom argue that proprietary pricing information is competitively sensitive. Manufacturers contend that disclosing net prices would reveal their negotiating positions, reducing their leverage and potentially increasing prices as competitors benchmark against disclosed rates. PBMs argue that rebate disclosure would disrupt the contracting dynamics that generate savings for plan sponsors. Both arguments have surface plausibility and are also self-serving, which makes them difficult to evaluate without the very data that the parties are refusing to disclose.
The data that has been disclosed has proven difficult for the intended audiences — legislators, regulators, the public — to interpret. Drug pricing is not a domain where raw data converts easily to policy insight. A state legislator reviewing a manufacturer’s filing on a specialty oncology drug faces a stack of financial data that requires expertise in pharmaceutical economics, reimbursement systems, and supply chain dynamics to evaluate meaningfully. Legislative staff may lack this expertise. Regulatory agencies may lack the resources to analyze filings across hundreds of products. The data sits in filings, technically transparent and practically opaque.
The interaction between state transparency laws and federal pricing systems adds complexity. WAC is a national price set by the manufacturer. A state law that scrutinizes WAC increases cannot compel the manufacturer to set a different national price for that state — it can only require disclosure of the pricing rationale. If the disclosure triggers political pressure that leads a manufacturer to moderate a price increase, the law has achieved its behavioral objective without formal enforcement. If the manufacturer files the required justification and proceeds with the increase regardless, the law has produced a filing cabinet of disclosures with limited policy impact.
A few states have gone further, establishing drug affordability review boards with the authority to set upper payment limits for drugs whose prices are deemed unaffordable. These bodies — modeled loosely on public utility rate-setting commissions — represent a more interventionist approach that goes beyond transparency to actual price regulation. Their legal authority is being tested in courts, and their practical impact depends on implementation details: which drugs are reviewed, what criteria define “affordability,” and whether the payment limits apply to state programs only or to all payers in the state.
What the transparency movement has accomplished, even where the laws have not produced their intended behavioral effects, is the creation of a data infrastructure that did not previously exist. State-level pricing disclosures, however imperfect, constitute a body of reported data about drug pricing decisions that researchers, journalists, and advocacy organizations can access and analyze. Over time, the accumulated filings may support longitudinal studies of pricing behavior, competitive dynamics, and the relationship between WAC changes and net price changes that the cross-sectional data cannot capture.
The gap between transparency and accountability is not a failure of the laws. It is a consequence of the system’s complexity. Drug pricing in the United States involves too many actors, too many moving parts, and too many proprietary data streams for disclosure of any single variable to produce the clarity that the word “transparency” implies. The data is becoming more available. The interpretive framework to make sense of it is lagging behind.
